Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): An analysis of their neuropsychobiological interactions in recreational users

Journal of Neural Transmission

Volumn 114, Issue 8, 2007, Pages 959-968

  Parrott, A C ^a   Milani, R M ^b   Gouzoulis Mayfrank, E ^c   Daumann, J ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WEST LONDON   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antioxidant; Cannabinoid; Cannabis; Cognition; Ecstasy; Hyperthermia; MDMA; Oxidative stress; Serotonin; Temperature

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPA RECEPTOR; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; ILLICIT DRUG; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PSYCHEDELIC AGENT;

ALERTNESS; ANALYTIC METHOD; ANTIOXIDANT ACTIVITY; AROUSAL; BODY TEMPERATURE; DRUG ABUSE; HUMAN; HYPERTHERMIA; HYPOTHERMIA; INCIDENCE; NERVE CELL STIMULATION; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROPSYCHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SEDATION; SOCIAL PSYCHOLOGY;

ANIMALS; CANNABIS; CYTOPROTECTION; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DRUG INTERACTIONS; FEVER; HALLUCINOGENS; HUMANS; MARIJUANA ABUSE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATIVE STRESS; RISK FACTORS;

EID: 34547117589     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-007-0715-7     Document Type: Review

References (101)

1. A Agrawal MC Neale CA Prescott KS Kendler 2004 A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs Psychol Med 34 1227 1237
2. S Bhattachary JH Powell 2001 Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or "ecstasy": evidence for cognitive impairment Psychol Med 31 647 658
3. KI Bolla UD McCann GA Ricaurte 1998 Memory impairment in abstinent MDMA ("Ecstasy") users Neurology 51 1532 1537
4. A Boys J Marsden J Strang 2001 Understanding reasons for drug use amongst young people: a functional perspective Health Ed Res 16 457 469
5. D Braida M Sala 2002 Role of the endocannabinoid system in MDMA intracerebral self-administration in rats Br J Pharmacol 136 1089 1092
6. D Braida S Iosue S Pegorini M Sala 2005 3,4- Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system Pharmacol Res 51 177 182
7. MI Colado J Camarero AO Mechan V Sanchez B Esteban JM Elliott AR Green 2001 A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain Br J Pharmacol 134 1711 1723
8. RJ Croft AJ Mackay ATD Mills JGH Gruzelier 2001 The relative contributions of ecstasy and cannabis to cognitive impairment Psychopharmacology 153 373 379
9. JL Croxford 2003 Therapeutic potential of cannabinoids in CNS disease CNS Drugs 17 179 202
10. V Curran 2000 Is MDMA ("Ecstasy") neurotoxic in humans? An overview of evidence and of methodological problems in research Neuropsychobiology 42 34 41
11. RI Dafters R Hoshi AC Talbot 2004 Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users Psychopharmacology 173 405 410
12. J Daumann S Pelz S Becker F Tuchtenhagen E Gouzoulis-Mayfrank 2001 Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use Hum Psychopharmacol 16 627 633
13. J Daumann R Schnitker J Weidemann K Schnell A Thron E Gouzoulis-Mayfrank 2003 Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users Neuro Report 14 1983 1987
14. J Daumann G Hensen B Thimm M Rezk B Till E Gouzoulis-Mayfrank 2004 Self-reported psychopathological symptoms in abstinent recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation Psychopharmacology 173 398 404
15. G Dughiero F Schifano G Forza 2001 Personality dimensions and psychopathological profiles of Ecstasy users Hum Psychopharmacol 16 635 639
16. H Fox AC Parrott JJD Turner 2001 Ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems J Psychopharmacol 15 273 281
17. HC Fox A McLean JJD Turner AC Parrott R Rogers BJ Sahakian 2002 Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users Psychopharmacology 162 203 214
18. RR Freedman CE Johanson ME Tancer 2005 Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans Psychopharmacology 183 248 256
19. G Gerra L Angioni A Zaimovic G Moi M Bussandri S Bertacca G Santoro S Gardini R Caccavari MA Nicoli 2004 Substance use among high-school students: relationships with temperament, personality traits, and parental care perception Subst Use Misuse 39 345 367
20. Y Gilgun-Sherki E Melamed D Offen 2001 Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier Neuropharmacology 40 959 975
21. E Gouzoulis-Mayfrank J Daumann F Tuchtenhagen S Pelz S Becker H-J Kunert B Fimm H Sass 2000 Impaired cognitive performance in drug-free recreational ecstasy (MDMA) users J Neurosurg Psychiatry 68 719 725
22. E Gouzoulis-Mayfrank B Thimm M Rezk G Hensen J Daumann 2003 Memory impairment suggests hippocampal dysfunction in abstinent ecstasy (MDMA) users Prog Neuropsychopharmacol Biol Psychiatry 27 819 827
23. E Gouzoulis-Mayfrank J Daumann 2006 The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview J Psychopharmacol 20 188 193
24. AR Green AJ Cross GM Goodwin 1995 Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) Psychopharmacology 119 247 260
25. AR Green AO Mechan JM Elliott E O'Shea MI Colado 2003 The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") Pharmacol Revs 55 463 508
26. RI Grundy 2002 The therapeutic potential of the cannabinoids in neuroprotection Expert Opin Investig Drugs 11 1365 1374
27. RI Grundy M Rabuffetti M Beltramo 2001 Cannabinoids and neuroprotection Mol Neurobiol 24 29 51
28. W Hall N Solowij 1998 The adverse effects of cannabis Lancet 352 1611 1616
29. JH Halpern HG Pope AR Sherwood S Barry JI Hudson D Yurgelun-Todd 2004 Residual effects of illicit 3,4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs Drug Alcohol Depend 75 135 148
30. AJ Hampson M Grimaldi J Axelrod D Wink 1998 Cannabidiol and (-) Delta 9-tetrahydrocannabinol are neuroprotective antioxidants Proc Natl Acad Sci USA 95 8268 8273
31. AJ Hampson M Grimaldi M Lolic D Wink R Rosenthal J Axelrod 2000 Neuroprotective antioxidants from marijuana Ann NY Acad Sci USA 899 274 282
32. KL Hanson M Luciana 2004 Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use Psychol Med 34 229 246
33. K Hayakawa K Mishima K Abe N Hasebe F Takamatsu H Yasuda T Ikeda K Inui N Egashira K Iwasaki M Fujiwara 2004 Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism Neuro Report 25 2381 2385
34. KM Hegadoren GB Baker M Bourin 1998 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans Neurosci Biobehav Revs 23 539 553
35. G Huether D Zhou E Ryuther 1997 Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners J Neural Transm 104 771 794
36. BC Kelly JT Parsons BE Wells 2006 Prevalence and predictors of club drug use among club-going young adults in New York city J Urban Health 83 884 895
37. JH Krystal LH Price 1992 Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18 331 341
38. R Lieb CG Schuetz H Pfister K von Sydow H-U Wittchen 2002 Mental disorders in ecstasy users: a prospective-longitudinal investigation Drug Alcohol Depend 68 195 207
39. Martins SS, Ghandour LA, Chilcoat HD (2006) Pathways between ecstasy initiation and other drug. Addict Behav [Epub ahead of print]
40. UD McCann Z Szabo U Scheffel RF Dannals GA Ricaurte 1998 Positron Emission tomographic evidence of toxic effects of MDMA ('ecstasy') on brain serotonin neurons in human beings Lancet 352 1433 1437
41. UD McCann V Eligulashvili GA Ricaurte 2000 3,4- Methylenedioxymethamphetamine ("Ecstacy")-induced serotonin neurotoxicity: clinical studies Neuropsychobiology 42 11 16
42. K McCardle S Luebbers JD Carter RJ Croft C Stough 2004 Chronic MDMA (ecstasy) use, cognition and mood Psychopharmacology 173 434 439
43. RM Milani JJD Turner AC Parrott R Parmar 2000 Recreational drug use and psychobiological problems, collaborative UK/Italy study: Ecstasy (MDMA) polydrug user findings J Psychopharmacol 14 A15
44. RM Milani AC Parrott JJD Turner 2002 Cannabis use in Ecstasy users Adiktologie 1 67 68
45. RM Milani AC Parrott F Schifano JJ Turner 2005 Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms Hum Psychopharmacol 20 249 261
46. MJ Morgan 1999 Memory deficits associated with recreational use of "ecstasy" (MDMA) Psychopharmacology 141 30 36
47. MJ Morgan L McFie LH Fleetwood JA Robinson 2002 Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159 294 303
48. KC Morley KM Li GE Hunt PE Mallet IS McGregor 2004 Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats Neuropharmacology 46 954 965
49. E O'Shea N Easton JR Fry AR Green CA Marsden 2002 Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia J Neurochem 81 686 695
50. AC Parrott 2001 Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research Hum Psychopharmacol 16 557 577
51. AC Parrott 2002 Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity Pharmacol Biochem Behav 71 837 844
52. AC Parrott 2003 Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users Hum Psychopharmacol 18 89 90
53. AC Parrott 2004a Is Ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity Psychopharmacology 173 234 241
54. AC Parrott 2004b MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves Neuropsychobiology 50 329 335
55. AC Parrott 2006 MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress J Psychopharmacol 20 147 163
56. AC Parrott 2007 Ecstasy versus alcohol: Tolstoy and the variations in unhappiness J Psychopharmacol 20 3 6
57. AC Parrott J Lasky 1998 Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance Psychopharmacology 139 261 268
58. AC Parrott L Young 2005 Increased body temperature in recreational Ecstasy/MDMA users out clubbing and dancing J Psychopharmacol 19 a26
59. AC Parrott A Lees NJ Garnham M Jones K Wesnes 1998 Cognitive performance in recreational users of MDMA or "ecstasy": evidence for memory deficits J Psychopharmacol 12 79 83
60. AC Parrott E Sisk JJD Turner 2000 Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users Drug Alc Depend 60 105 110
61. AC Parrott R Milani R Parmar JJD Turner 2001 Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems Psychopharmacology 159 77 82
62. AC Parrott E Gouzoulis-Mayfrank J Rodgers N Solowij 2004a Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects J Psychopharmacol 18 579 582
63. A Parrott A Morinan M Moss A Scholey 2004b Understanding drugs and behaviour Wiley Chichester
64. AC Parrott J Rodgers T Buchanan J Ling T Heffernan AB Scholey 2006 Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users Hum Psychopharmacol 21 285 298
65. W Pedersen A Skrondal 1999 Ecstasy and new patterns of drug use: a normal population study Addiction 94 1695 1706
66. W Pedersen SE Clausen NJ Lavik 1989 Patterns of drug use and sensation-seeking among adolescents in Norway Acta Psychiatr Scand 79 386 390
67. HG Pope AJ Gruber JI Hudson MA Huestis D Yurgelun-Todd 2001a Neuropsychological performance in long-term cannabis users Arch Gen Psychiatry 58 909 915
68. HG Pope M Ionescu-Pioggia KW Pope 2001b Drug use and lifestyle among college undergraduates: a 30 year longitudinal study Am J Psychiatry 158 1519 1520
69. M Ranganathan DC D'Souza 2005 The acute effects of cannabinoids on memory in humans: a review Psychopharmacology 188 425 444
70. L Reneman J Booij B Schmand W van den Brink B Gunning 2000 Memory disturbances in "ecstasy" users are correlated with an altered brain serotonin neurotransmission Psychopharmacology 148 322 324
71. L Reneman J Lavalaye B Schmand FA de Wolff W van den Brink GJ den Heeten J Booij 2001 Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") Arch Gen Psychiatry 58 901 906
72. L Reneman MM de Win W van den Brink J Booij GJ den Heeten 2006 Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects J Psychopharmacol 20 164 175
73. CL Renfroe 1986 MDMA on the street: analysis anonymous J Psychoact Drugs 18 363 369
74. GA Ricaurte G Bryan L Strauss LS Seiden CR Schuster 1985 Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals Science 229 986 988
75. GA Ricaurte J Yuan UD McCann 2000 (+)-3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") - induced serotonin neurotoxicity: studies in animals Neuropsychobiology 42 5 10
76. J Rodgers 2000 Cognitive performance amongst recreational users of "ecstasy" Psychopharmacology 151 19 24
77. J Rodgers T Buchanan AB Scholey TM Heffernan J Ling AC Parrott 2001 Differential effects of Ecstasy and cannabis on self-reports of memory ability: a web-based study Hum Psychopharmacol 16 619 625
78. J Rodgers T Buchanan C Pearson AC Parrott J Ling TM Heffernan AB Scholey 2006 Differential experiences of the sequelae of ecstasy use: quantitative and qualitative data from an internet study J Psychopharmacol 20 437 446
79. M Sala D Braida 2005 Endocannabinoids and 3,4- methylenedioxymethamphetamine (MDMA) interaction Pharmacol Biochem Behav 81 407 416
80. F Schifano 2000 Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies Neuropsychobiology 42 25 33
81. CJ Schmidt 1987 Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine J Pharmacol Exp Ther 240 1 7
82. AB Scholey AC Parrott T Buchanan T Heffernan J Ling J Rodgers 2004 Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a www study Addict Behav 29 743 752
83. P Schuster R Lieb C Lamertz HU Wittchen 1998 Is the use of ecstasy and hallucinogens increasing? Eur Addict Res 4 75 82
84. DM Semple KP Ebmeier MF Glabus RE O'Carroll EC Johnstone 1999 Reduced in vivo binding to serotonin transporters in the cerebral cortex of MDMA ("ecstasy") users Br J Psychiatry 175 63 69
85. NG Simon RP Mattick 2002 The impact of regular ecstasy use an memory function Addiction 97 1523 1529
86. N Solowij RS Stephens RA Roffman T Babor R Kadden M Miller K Christiansen B McRee J Vendetti the Marijuana Treatment Project Research Group 2002 Cognitive functioning of long-term heavy cannabis users seeking treatment JAMA 287 1123 1131
87. JE Sprague SL Everman DE Nichols 1988 An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine Neurotoxicology 19 427 421
88. J Strote JE Lee H Wechsler 2002 Increasing MDMA use among college students: results of a national survey J Adolesc Health 30 64 72
89. Tancer ME, Johanson CE, Freedman RR (2003) MDMA elevates core temperature in warm and cold conditions in man. College on Problems of Drug Dependence Annual Conference. Florida USA, June 2003. Conference Abstract, p 169
90. R Thomasius K Petersen R Buchert B Andresen P Zapletalova L Wartberg B Nebeling A Schmoldt 2003 Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users Psychopharmacology 167 85 96
91. L Topp J Hando P Dillon A Roche N Solowij 1999 Ecstasy use in Australia: patterns of use and associated harm Drug Alcohol Depend 55 105 115
92. M Van der Stelt WB Veldhuis PR Bar GA Veldink JF Vliegenthart K Nicolay 2001 Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity J Neurosci 21 6475 6479
93. FA Wagner JC Anthony 2002 In to the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine Am J Epidemiol 155 918 925
94. M Wareing M Fisk JE Murphy 2000 Working deficits in current & previous users of MDMA ('ecstasy') Br J Psychol 91 181 188
95. HC Wilcox FA Wagner JC Anthony 2002 Exposure opportunity as a mechanism linking youth marijuana use to hallucinogen use Drug Alcohol Depend 66 127 135
96. AR Winstock P Griffiths D Stewart 2001 Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK Drug Alcohol Depend 64 9 17
97. ED Wish DB Fitzelle KE O'Grady MH Hsu AM Arria 2006 Evidence for significant polydrug use among ecstasy-using college students J Am Coll Health 55 99 104
98. J Yip T Lee 2005 The effects of ecstasy use on neuropsychological function: a study in Hong Kong Psychopharmacology 179 620 628
99. KK Zakzanis DA Young 2001 Memory impairment in abstinent MDMA ("ecstasy") users: a longitudinal investigation Neurology 56 966 969
100. KK Zakzanis Z Campbell 2006 Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up Neurology 66 740 741
101. JF Zhou P Chen YH Zhou L Zhang HH Chen 2003 3,4- Methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage Free Radic Res 37 491 497